Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1017/S0963180108080328 | DOI Listing |
Sci Rep
December 2024
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Focusing on the Yashkun population of Gilgit-Baltistan, an administrative territory in northern Pakistan, our study investigated mtDNA haplotypes as indicators of ancient gene flow and genetic diversity. Genomic DNA was extracted and evaluated for quality using agarose gel electrophoresis. The complete control region of mtDNA (nt 16024-576) was amplified via PCR, and sequencing was performed using the Big Dye Terminator Kit on an Applied Biosystems Genetic Analyzer.
View Article and Find Full Text PDFPLoS One
December 2024
College of Nursing, Yonsei University, Seoul, Republic of Korea.
Background: Participants' satisfaction is an important factor in securing competitiveness in clinical trials. In many industries, such as healthcare, customer service quality has been analyzed to increase customer satisfaction. However, no study so far has attempted to measure participants' perceptions of service quality in the clinical trial area and identify its effect on participant satisfaction.
View Article and Find Full Text PDFInt J Equity Health
December 2024
Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, Utrecht University Medical Center, Utrecht University, Utrecht, The Netherlands.
Background: The use of urban green spaces differs by social characteristics, including gender, ethnicity, and socioeconomic position. We examined motives, means and prerequisites to visit green space of marginalised populations with high cardiometabolic risk in the Netherlands, namely women with a Turkish or South Asian Surinamese background residing in disadvantaged neighbourhoods.
Methods: We conducted six focus group discussions in two Dutch cities.
Clin Drug Investig
November 2024
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden.
Background And Objective: Mitiperstat (AZD4831) is a novel irreversible oral myeloperoxidase inhibitor in clinical development for heart failure with preserved ejection fraction, metabolic dysfunction-associated steatohepatitis and chronic obstructive pulmonary disease. This study evaluated the pharmacokinetics, safety and tolerability of multiple ascending doses of mitiperstat in healthy male Japanese and Chinese volunteers.
Methods: Three cohorts of eight Japanese participants were randomized to receive once-daily oral doses of mitiperstat 2.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!